Consensus Alkermes plc

Stocks

ALKS

IE00B56GVS15

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-24 EDT			5-day change	1st Jan Change
52.89 ^USD	-0.15%		+0.32%	+89.03%

07-13	Alkermes Announces Interim Results From Long-Term Extension Study Of Alixorexton In Adults With Narcolepsy Type 1 And Type 2	CI
07-13	Alkermes Public's Alixorexton Demonstrates Durable Efficacy in Narcolepsy Patients	MT

Evolution of the Average Target: Alkermes plc

Evolution of the Target Price: Alkermes plc

Changes in Analyst Recommendations: Alkermes plc

bb96d04336369fc8c9caf06b6d54.O6FcH2TZRvEbpv847tdOetuFPQLPs9LIC20mnAT9M1k.duMQKjeSH8dywrZnobMNM7LsblGJ6oqxbwZL-UCcR25klyksV78RrnDllA~b7f5e40d4749d8e5de930781db6cb708

Analysts' recommendations: Alkermes plc

06-29	Alkermes Faces Risk on Orexin-Related Value From Upcoming Updates, BofA Says	MT
06-29	BofA Securities Downgrades Alkermes to Underperform From Neutral, $38 Price Target	MT
06-22	Deutsche Bank Lifts Alkermes Price Target to $60 From $47, Maintains Buy Rating	MT
06-09	Alkermes' Orexin May Have Applicability Outside Sleep, RBC Says	MT
06-09	RBC Raises Price Target on Alkermes to $56 From $45, Keeps Outperform Rating	MT
05-06	Alkermes' Q1 Revenue Beat Highlights 'Underappreciated' Core Business, RBC Says	MT
05-06	UBS Adjusts Price Target on Alkermes Public to $48 From $42, Maintains Buy Rating	MT
04-09	BofA Adjusts Price Target on Alkermes Public to $36 From $34, Maintains Neutral Rating	MT
04-07	RBC Capital Adjusts Price Target on Alkermes Public to $44 From $45, Maintains Outperform Rating	MT
02-26	RBC Lowers Price Target on Alkermes to $45 From $47, Keeps Outperform Rating	MT
02-18	Deutsche Bank Adjusts Alkermes Price Target to $42 From $43, Maintains Buy Rating	MT
11-19	Alkermes Faces Pressure to Secure the Buyout of Avadel After Lundbeck's Unsolicited Bid, RBC Says	MT
11-17	Truist Raises Price Target on Alkermes to $55 From $50, Keeps Buy Rating	MT
11-13	Deutsche Bank Lowers Price Target on Alkermes to $45 From $55, Keeps Buy Rating	MT
11-11	Truist Initiates Alkermes at Buy With $50 Price Target	MT
25-10-29	Deutsche Bank Adjusts Alkermes Price Target to $55 From $53, Maintains Buy Rating	MT
25-10-23	RBC Raises Price Target on Alkermes to $47 From $45, Keeps Outperform Rating	MT
25-10-08	RBC Lifts Price Target on Alkermes to $45 From $44, Keeps Outperform Rating	MT
25-09-26	Alkermes' Stock Dip on Narcolepsy Data Seen as Buying Opportunity, RBC Says	MT
25-09-26	RBC Capital Upgrades Alkermes to Outperform From Sector Perform, Adjusts PT to $44 From $42	MT
25-09-03	Wells Fargo Initiates Alkermes Public at Overweight With $44 Price Target	MT
25-07-30	RBC Raises Price Target on Alkermes to $42 From $40, Keeps Sector Perform Rating	MT
25-06-17	UBS Upgrades Alkermes Public to Buy From Neutral, Adjusts Price Target to $42 From $33	MT
25-05-28	Needham Initiates Alkermes Public at Buy With $45 Price Target	MT
25-05-02	RBC Raises Price Target on Alkermes to $40 From $39, Keeps Sector Perform Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ALKERMES PLC					+1.32%
	LONZA GROUP AG					+23.65%
	REVOLUTION MEDICINES, INC.					+9.39%
	BEONE MEDICINES AG					+27.54%
	IQVIA HOLDINGS INC.					+11.51%
	CELLTRION, INC.					+44.52%
	MEDPACE HOLDINGS, INC.					-5.11%
	ASCENDIS PHARMA A/S					+19.91%
	EUROFINS SCIENTIFIC SE					+8.58%
	ICON PUBLIC LIMITED COMPANY					+9.68%
	Average					+15.10%
	Weighted average by Cap.					+18.18%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

52.89USD

Average target price

53.59USD

Spread / Average Target

+1.32%

High Price Target

65.00USD

Spread / Highest target

+22.90%

Low Price Target

38.00USD

Spread / Lowest Target

-28.15%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

BofA Securities
Deutsche Bank Securities
RBC Capital Markets
UBS
Truist Securities
Wells Fargo Securities
Needham & Co.
Stifel Nicolaus
TD Cowen
Cantor Fitzgerald
Baird
Piper Sandler
Evercore ISI
Mizuho Securities
HC Wainwright
JPMorgan Chase
SVB Leerink
Goldman Sachs
Citigroup